HC Wainwright Reaffirms "Buy" Rating for uniQure (NASDAQ:QURE)

HC Wainwright reiterated their buy rating on shares of uniQure (NASDAQ:QURE - Free Report) in a research note released on Monday,Benzinga reports. They currently have a $70.00 price target on the biotechnology company's stock.

QURE has been the topic of several other research reports. Chardan Capital initiated coverage on shares of uniQure in a research report on Tuesday, April 1st. They set a "buy" rating and a $38.00 price objective on the stock. Royal Bank of Canada restated an "outperform" rating and set a $24.00 price target on shares of uniQure in a research report on Tuesday, January 21st. StockNews.com raised uniQure to a "sell" rating in a report on Tuesday, March 11th. Finally, Wells Fargo & Company cut their target price on uniQure from $35.00 to $30.00 and set an "equal weight" rating for the company in a research note on Friday, February 28th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, uniQure presently has an average rating of "Moderate Buy" and a consensus price target of $38.80.

uniQure Price Performance

uniQure stock traded down $0.08 during midday trading on Monday, reaching $14.18. 646,241 shares of the stock were exchanged, compared to its average volume of 1,777,921. The company's fifty day moving average is $11.94 and its 200-day moving average is $11.54. The company has a debt-to-equity ratio of 0.92, a quick ratio of 6.51 and a current ratio of 6.51. uniQure has a 52 week low of $3.73 and a 52 week high of $19.18. The firm has a market cap of $766.81 million, a PE ratio of -2.86 and a beta of 0.42.

Insider Transactions at uniQure

In other news, CEO Matthew C. Kapusta sold 6,717 shares of the business's stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $11.32, for a total value of $76,036.44. Following the completion of the transaction, the chief executive officer now directly owns 580,795 shares of the company's stock, valued at approximately $6,574,599.40. The trade was a 1.14 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Christian Klemt sold 14,341 shares of the firm's stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $10.70, for a total transaction of $153,448.70. Following the completion of the sale, the chief financial officer now owns 152,372 shares of the company's stock, valued at approximately $1,630,380.40. This trade represents a 8.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 90,830 shares of company stock worth $961,401. 4.74% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On uniQure

Institutional investors have recently bought and sold shares of the business. Avoro Capital Advisors LLC purchased a new stake in uniQure in the 4th quarter worth approximately $38,410,000. Franklin Resources Inc. acquired a new position in shares of uniQure in the 3rd quarter valued at $7,360,000. RTW Investments LP boosted its holdings in uniQure by 8,936.3% during the fourth quarter. RTW Investments LP now owns 903,625 shares of the biotechnology company's stock worth $15,958,000 after buying an additional 893,625 shares in the last quarter. Point72 Asset Management L.P. increased its holdings in uniQure by 81.3% in the fourth quarter. Point72 Asset Management L.P. now owns 1,771,352 shares of the biotechnology company's stock valued at $31,282,000 after buying an additional 794,459 shares in the last quarter. Finally, Boxer Capital Management LLC acquired a new position in shares of uniQure in the fourth quarter worth about $13,245,000. 78.83% of the stock is owned by hedge funds and other institutional investors.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.